Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry.

Trial Profile

Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms EVHALAVEN
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 11 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Sep 2015 According to an Eisai media release, data from this study will be presented at the 18th Biennial Congress of European Cancer Congress (ECC).
    • 18 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top